TOKYO, May 28 (Pulse News Wire) – Adr120s,inc. (3750.T) announced today that its subsidiary, ADR Therapeutics Co., Ltd., located at Tokyo, Chiyoda Ku Koujimachi 2-3-3, has secured an order for two Cellation Centrifuge units from a newly established clinic focusing on regenerative medicine.
The clinic plans to open and commence operations by the end of June 2026, with the delivery scheduled for June 20, 2026. The Cellation Centrifuge units enable rapid processing of cell clusters containing stem cells from adipose tissue.
The contract's total sales revenue is expected to amount to ¥40 million, representing approximately 80% of ADR120S’s previous fiscal year's revenue (ended March 2026). The company anticipates recognizing the revenue upon completion of product delivery during the first quarter of the fiscal year ending March 2027.
While this transaction is already reflected in the forecast for the fiscal year ending March 2027, ADR120S will promptly disclose any significant developments related to this agreement.
🟢 Confidence: High AI-translated content.